036 - Response of cartilage oligomeric matrix protein (COMP) to infliximab or adalimumab in patients with Rheumatoid Arthritis: impact of biological variability
Autor(s): M. Tampoia, V. Brescia, P. Falappone, A. Zucano, A. Fontana, G. Lapadula, F. Diserio
Issue: RIMeL - IJLaM, Vol. 4, N. 1, 2008 (MAF Servizi srl ed.)
Page(s): 36-42
Background. Cartilage oligomeric matrix protein (COMP) is a biomarker for the cartilage turnover and is described as a valuable parameter for the assessment of response to therapy in patients with rheumatoid arthritis (RA). The aim of this study was to assess the impact of reference change value (RCV) to evaluate the changes in serum-COMP following infliximab or adalimumab treatment in patients with RA. Methods. Thirty-one patients with established RA, were studied before and after 6 months from treatment. Twenty-one of them received infliximab and ten adalimumab. Serum-COMP was measured by ELISA (COMP Assay, Menarini). The RCV data (95% confidence), was obtained from literature. Results. After 6 months on treatment, serum-COMP decreased significantly in ACR responder patients. The average decrease, calculated for each individual patient, showed that serum-COMP changed more than RCV in 39.1% of patients who responded to treatment. Conclusions. The COMP is potentially a marker for monitoring response to therapy in patients with rheumatoid arthritis (RA). The calculation of RCV is important to determine how they responded.